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INTRODUCTION 
The following scene takes place at a common pharmacy 
counter. 
Pharmacist: “There is a generic formulation of this drug.  
Would you like to buy it instead of the brand-name prescription?” 
Consumer: “How much would I save if I bought the generic 
drug?” 
 
Americans are concerned with the cost of drugs.1  Currently, 
America’s health care spending is about $2 trillion, and in ten 
years, is expected to roughly double to $4.1 trillion.2  To put that 
into perspective, we spend about $7,500 per capita on health care 
 
A PDF version of this Note is available online at http://iplj.net/blog/archives/ 
volumexx/book1.  Visit http://iplj.net/blog/archives for access to the IPLJ archive. 
*  J.D. Candidate, Fordham University School of Law, 2010; Ph.D., Biochemistry, 
Molecular and Cell Biology, Cornell University, 2007; A.B., Vassar College, 2001.  
Many thanks to Professors John J. Normile, Partner at Jones Day, and Brian Coggio, 
Senior Principal at Fish & Richardson P.C., for their guidance. 
 1 See, e.g., Andrew Pollack, Costly Drugs Known as Biologics Prompt Exclusivity 
Debate, N.Y. TIMES, July 22, 2009, at B1, available at http://www.nytimes.com/ 
2009/07/22/business/22biogenerics.html?pagewanted=all. 
 2 Orrin G. Hatch, U.S. Sen., Remarks Before the U.S. Chamber of Commerce, The 
Future of Biologics—Examining Market Competition, Innovation, and Patient Safety 
(Apr. 25, 2007), available at http://www.votesmart.org/speech_detail.php?sc_id=279366 
&keyword=&phrase=&contain. 
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in the United States.3  These figures are expected to rise to $12,800 
per capita in 2016.4  Much of this increase is expected because of 
greater spending for pharmaceuticals.5  With such a large amount 
of national spending invested in healthcare, the millions of 
uninsured or solely Medicaid-covered Americans have a great 
stake in the price of medication.6  Citizens and legislators are 
concerned because “[p]rices are inexorably linked to healthcare, 
monetary and fiscal policy, management of national debt, and, 
ultimately, overall standard of living.”7  Thus, the rapid rise in 
healthcare spending is a deep concern for citizens, drug companies, 
healthcare providers, and politicians.8 
To bring a new, innovative drug to market, a pharmaceutical 
company needs to spend huge sums of money on research and 
development.9  Thousands of chemicals are routinely synthesized 
in laboratories with the hope that just one chemical will provide a 
benefit to Americans.10  Then, labs send the chemical through a 
barrage of experimentation for characterization.11  Researchers, 
drug companies, and the United States Food and Drug 
Administration (“FDA”) need to answer the following questions: 
what does this chemical do?  And, does this drug generate any 
undesirable effects?  After years of testing, very few chemicals are 
 
 3 Id. 
 4 Id. 
 5 Id. 
 6 See NLM Gateway, Out-of-Pocket Price, Prescription Medications and Seniors, 
http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102275591.html (last visited Aug. 
30, 2009). 
 7 A. Taylor Corbitt, The Pharmaceutical Frontier: Extending Generic Possibilities to 
Biologic Therapies in the Biologics Price Competition and Innovation Act of 2007, 18 
DEPAUL J. ART TECH. & INTELL. PROP. L. 365, 370 (2008). 
 8 Id. 
 9 Joseph A. DiMasi, Ronald W. Hansen & Henry G. Grabowski, The Price of 
Innovation: New Estimates of Drug Development Costs, 22 J. HEALTH ECON. 151, 151 
(2003) (“The estimated average out-of-pocket cost per new drug is US$ 403 million 
(2000 dollars).  Capitalizing out-of-pocket costs to the point of marketing approval at a 
real discount rate of 11% yields a total pre-approval cost estimate of US$ 802 million 
(2000 dollars).”). 
 10 U.S. CONG. BUDGET OFFICE, A CBO STUDY: RESEARCH AND DEVELOPMENT IN THE 
PHARMACEUTICAL INDUSTRY 2 (2006), available at http://www.cbo.gov/ftpdocs/ 
76xx/doc7615/10-02-DrugR-D.pdf. 
 11 Id. 
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still contenders for FDA approval.12  This tumultuous story of 
innovative drug synthesis and testing occurs everyday, as the 
industry is constantly looking for the diamond in the rough.  As a 
result,  pharmaceutical companies invest more and more money13 
with the hope that after years of work, innovative drugs will allow 
them to pay back the deficit caused by research and development. 
Few chemicals are able to be considered medicines.14  When an 
invention is patented, the inventor must disclose information 
permitting others to replicate the invention.15  In return, the 
inventor receives the right to exclude others from making, using, 
marketing, and offering for sale or importing the invention.16  The 
Hatch-Waxman Act,17 which amended the Public Health Service 
Act (“PHSA”),18 loosened the exclusivity rights of the patentee by 
permitting other pharmaceutical companies to produce identical 
chemicals, “follow-on drugs,”19 faster by permitting them to 
bypass FDA testing.20  This Act has permitted consumers to 
choose between brand-name and generic drugs earlier, driving 
down the cost of drugs by price competition.21  However, the drugs 
in question have mainly been generated in vitro, in glass tubes.22  
 
 12 See DiMasi et al., supra note 9, at 159. 
 13 In late 2005, it was estimated that about $95 billion was spent per year on medical 
research. Associated Press, $95 Billion a Year Spent on Medical Research, MSNBC, 
Sept. 20, 2005, http://www.msnbc.msn.com/id/9407342/. 
 14 Boehringer Ingelheim, Drug Discovery Process, http://www.boehringer-
ingelheim.com/corporate/research/drug_discovery_process.asp (last visited Sept. 27, 
2009) (stating that only one in over a million screened molecules is investigated in late 
stage clinical trials and made available to patients). 
 15 35 U.S.C. § 112 (2006). 
 16 Id. § 154(a)(1). 
 17 Drug Price Competition and Patent Term Restoration (Hatch-Waxman) Act of 1984, 
Pub. L. No. 98-417, 98 Stat. 1585 (codified as amended in scattered sections of 15, 21, 
28, 35 U.S.C.). 
 18 Public Health Service Act (PHSA), Pub. L. No. 111-43, 58 Stat. 682 (1944). 
 19 Follow-on drugs are drugs that are replicated from a non-innovative pharmaceutical 
company to compete with the brand-name drug on the market. See Donald Zuhn, Deloitte 
White Paper Addresses Unintended Consequences of Follow-on Biologic Regulatory 
Pathway, PATENT DOCS, Aug. 27, 2009, http://www.patentdocs.org/2009/08/deloitte-
white-paper-addresses-unintended-consequences-of-followon-biologic-regulatory-
pathway.html. 
 20 Id. 
 21 Id. 
 22 See infra note 39 and accompanying text. 
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Since the Hatch-Waxman Act was enacted, a new hurdle has 
surfaced: should patentees of biologics, or molecules synthesized 
in vivo (in cells), also have loosened exclusivity rights? 
This Note explores why generic biologics should be tested for 
FDA approval as rigorously as brand-name biologics.  This Note 
argues that the FDA should require the generic companies to 
provide experimental data showing that their isolated biological 
molecules have the same concentration, purity, potency, and 
activity as brand-name biologics. 
Part I highlights the legislation that makes drugs available to 
the public and examines how biological materials do not fit neatly 
into the current legislation.  Part II discusses present responses to 
the shortcomings of today’s legislation.  Finally, Part III offers 
prescriptions to manage this healthcare ailment. 
I. THE LONG AND WINDING ROAD OF CURRENT AND PENDING 
LEGISLATION 
The United States is facing a time of change regarding health 
care reform.23  There has been a working system in place to permit 
the approval of innovative small-molecule drugs, but new 
technology does not fit neatly into this system.24  Accordingly, one 
must have a comprehensive understanding of current law to best 
understand how policies play to the opposing interests of the 
innovative and non-innovative pharmaceutical industries. 
A. Testing Innovative Drugs 
Branded drugs come to the public through innovation.  There 
are two main parts to the process: research and development, and 
clinical testing.25  The pre-clinical phase of development starts 
with basic discovery through research, using both in vitro (in glass) 
 
 23 The White House—Health Care Reform, The President’s Plan, 
http://www.whitehouse.gov/issues/health_care/ (last visited Sept. 27, 2009) (detailing 
President Barack Obama’s health care reform plan). 
 24 BIO, BIO Principles on Follow-On Biologics, http://www.bio.org/healthcare/ 
followonbkg/Principles.asp (last visited Oct. 13, 2009). 
 25 Manthan D. Janodia, Drug Development Process: A Review (Dec. 25, 2007), 
http://www.pharmainfo.net/reviews/drug-development-process-review. 
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and in vivo (in cells) studies.26  Once researchers identify and 
purify a candidate compound27 after screening against a specific 
biological target,28 researchers conduct animal studies for further 
testing.29  The company developing the drug can file an 
Investigational New Drug (“IND”) application after it obtains 
positive results from animal studies.30  The FDA then evaluates 
INDs and grants permission for the drug to be tested on humans.31  
Thus begins the clinical phases of testing, consisting of three 
mandatory separate phases.32 
Each of these phases weeds out drugs that are not suitable for 
general use within the public.33  Phase I clinical trials test for 
safety and tolerability of the drug in a small group of human 
subjects.34  Phase II trials continue testing for safety and 
tolerability, but also assess the preliminary efficacy of the drug in a 
much larger pool of volunteers afflicted with the targeted 
condition.35  Phase III clinical trials involve the largest pool of 
volunteers and are designed to evaluate the drug in a more diverse 
population, over a period of several years.36  The drugs that 
advance through these three phases are submitted as New Drug 
 
 26 Id. 
 27 A candidate compound is a chemical that provides a key breakthrough for 
consequent clinical trials. Franz F. Hefti, Requirements for a Lead Compound to Become 
a Clinical Candidate, BMC NEUROSCIENCE, Dec. 10, 2008,  http://www.ncbi.nlm. 
nih.gov/pmc/articles/PMC2604885/. 
 28 The Free Dictionary, Biological Target, http://encyclopedia.thefreedictionary.com/ 
Biological+target (last visited Sept. 24, 2009) (“A biological target is an enzyme, 
receptor or other protein that can be modified by an external stimulus.  The definition is 
context-dependent and can refer to the biological target of a pharmacologically active 
drug compound, or the receptor target of a hormone (like insulin).  The implication is that 
a molecule is “hit” by a signal and its behavior is thereby changed.  This term is 
commonly used in pharmaceutical research to describe the native protein in the body that 
is modified by a medicinal chemical.”). 
 29 Hefti, supra note 27. 
 30 Donna M. Gitter, Innovators and Imitators: An Analysis of Proposed Legislation 
Implementing an Abbreviated Approval Pathway for Follow-On Biologics in the United 
States, 35 FLA. ST. U. L. REV. 555, 565 (2008). 
 31 Id. 
 32 Id. 
 33 See id. at 565–66. 
 34 Id. at 565. 
 35 Id. at 565–66. 
 36 Id. at 566. 
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Applications (“NDA”s) and new Biologic License Applications 
(“BLA”s) to the FDA.37 
B.  The Differences Between Drugs and Biologics 
Since 1984, pharmaceutical companies have had an easier 
opportunity to generate, market, and sell follow-on, or generic, 
forms of brand name drugs.38  A drug is generally a small molecule 
that is synthesized in vitro.39  Drugs are simple, not requiring any 
of the chemical modifications that a cell would provide for 
complex proteins.40  A protein, however, is a large organic 
molecule that is created in vivo;41 hence, it is called a “biologic 
compound” or “biologic.”42  “When two chemically-synthesized 
drugs are proven bioequivalent, their safety and efficacy can be 
assumed because two identical drugs will consistently produce the 
same reactions.  However, biologics do not have such 
characteristics.”43 
The structure of a protein is dictated by a series of complex 
folding patterns, and is generated as the protein is being 
synthesized.44  Additionally, many proteins within the cell also 
 
 37 Id. 
 38 See Drug Price Competition and Patent Term Restoration Act of 1984, 98 Stat. 1585 
(codified at 21 U.S.C. §§ 355, 360cc; 28 U.S.C. § 2201; 35 U.S.C. §§ 156, 271, 282 
(2006)). 
 39 BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL 472 (4th ed. 2002).   “In 
vitro” reactions are carried out in a test tube in the absence of living cells. Id. 
 40 Ronald A. Rader, Biopharmaceutical Terminology: What is a Biopharmaceutical? 
Part I: (Bio) Technology-Based Definitions, BIOEXECUTIVE INT’L, Mar. 2005, at 61–62, 
available at http://www.biopharma.com/BioExec_pt1.pdf. 
 41 ALBERTS ET AL., supra note 39, at 472.  “In vivo” reactions take place inside a living 
cell. Id. 
 42 National Cancer Institute, Dictionary of Cancer Terms, http://www.nci.nih.gov/ 
templates/db_alpha.aspx?CdrID=426407 (last visited Oct. 30, 2009).  A biological drug 
is “a substance made from a living organism or its products and is used in the prevention, 
diagnosis, or treatment of cancer and other diseases.” Id. 
 43 Kathleen R. Kelleher, FDA Approval of Generic Biologics: Finding a Regulatory 
Pathway, 14 MICH. TELECOMM. & TECH. L. REV. 245, 254 (2007). 
 44 See DAVID L. NELSON & MICHAEL M. COX, LEHNINGER PRINCIPLES OF 
BIOCHEMISTRY 159–200 (3d ed. 2000). 
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require the placement of sugars or fatty acid moieties45 on specific 
regions for proper function.46  Because of the complexity of 
generating proteins, it is impossible to create proteins using the 
same methodology as researchers use to create and mass-produce 
drugs.47 
Each protein has a highly specific and regulated function 
within the cell;48 as such, each protein is required to perform its 
intended job perfectly.49  When a protein malfunctions, the 
individual cell and the organism suffer.50  For example, when the 
cells within the pancreas fail to produce insulin, the person suffers 
from Type 1 diabetes mellitus.51  The only way to reverse the 
disease is to reintroduce insulin into the person’s body.52  Insulin is 
produced within cultured cells, harvested, and purified before 
being injected into the patient.53  This illustration reveals how the 
specificity of insulin controls a patient’s complete health.54 
One can easily characterize small molecules by using 
techniques of mass spectrometry, infrared spectrometry, nuclear 
magnetic resonance, and x-ray crystallography.55  “However, 
larger biologic molecules can be much more difficult to 
characterize in detail because they are more variable and 
 
 45 The Free Dictionary, Moiety, http://encyclopedia.thefreedictionary.com/moiety (last 
visited Oct. 30, 2009).  A moiety is a functional group, or part of a molecule, that is 
responsible for chemical reactions. See id. 
 46 NELSON & COX, supra note 44, at 1053–54. 
 47 Ed Zimney, Understanding Biologics: How They Differ From Drugs and Why They 
Cost More, EVERYDAY HEALTH, Dec. 2, 2008, http://www.everydayhealth.com/blog/ 
zimney-health-and-medical-news-you-can-use/understanding-biologics-how-they-differ-
from-drugs-and-why-they-cost-more/. 
 48 REGINALD H. GARRETT & CHARLES M. GRISHAM, BIOCHEMISTRY 158 (2d ed. 1999). 
 49 Id. 
 50 See id. at 159 (“[T]he primary structure facilitates the development of short-range 
interactions among adjacent parts of the sequence and also long-range interactions among 
distant parts of the sequence.”). 
 51 MedlinePlus, Diabetes Type 1, http://www.nlm.nih.gov/medlineplus/diabetestype1 
.html (last visited Aug. 27, 2009). 
 52 Janet M. Torpy, Cassio Lynm & Richard M. Glass, Type 1 Diabetes, 298 JAMA 
1472, 1472 (1997), available at http://jama.ama-assn.org/cgi/content/full/298/12/1472. 
 53 The Genetic Landscape of Diabetes, History of Diabetes, http://www.ncbi.nlm. 
nih.gov/bookshelf/br.fcgi?book=diabetes&part=A3 (last visited Oct. 31, 2009). 
 54 Id. 
 55 Kelleher, supra note 43, at 254. 
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complex . . . .”56  While analytical tests can determine structure, 
identity, purity, stability, and activity of such complex molecules, 
these assays do not determine the safety and efficacy of the 
product.57  Therefore, it is currently impossible to accurately 
predict the immunogenicity58 of a biologic without using clinical 
testing.59 
Supplying proteins to repair and save human lives is the new 
frontier in pharmaceutical companies.60  Therefore, it is necessary 
to determine variability between biologics produced within a 
generic pharmaceutical company and a brand name pharmaceutical 
company.61  A biologic is generally not a bioequivalent; however, 
it can be biosimilar.62 
Whereas generics of chemistry-based medicines are 
identical copies of the original product, based on a 
strict definition of “sameness,” a corresponding 
definition cannot be established for biosimilar 
medicines because of their nature and the 
complexity of their manufacturing process. . . .  
Because the manufacturing process of the products 
is so complex, extreme care must be taken to ensure 
that only medicines which have passed stringent 
safety and efficacy assessment, for example 
appropriate pre-clinical and clinical tests, are 
delivered to patients.63 
It is necessary for agencies, such as the FDA, to define the 
terms of biosimilarity to best protect the public. 
 
 56 Id. 
 57 Id. at 254–55. 
 58 The Free Dictionary, Immunogenicity, http://medical-dictionary.thefree 
dictionary.com/immunogenicity (last visited Oct. 31, 2009).  Immunogenicity is “the 
property enabling a substance to provoke an immune response, or the degree to which a 
substance possesses this property.” Id. 
 59 Kelleher, supra note 43, at 255. 
 60 See Biosimilars, Succeeding in the Market of the Future, http://www.pharma 
focusasia.com/research_development/biosimilars.htm (last visited Oct. 31, 2009). 
 61 See id. 
 62 Id. 
 63 EUROPABIO, HEALTHCARE BIOTECH FACT SHEET: BIOLOGICAL AND BIOSIMILAR 
MEDICINES 3 (2005), available at http://www.europabio.org/documents/FS-
Biosimilar.pdf. 
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C. Purifying Enriched Proteins for Use as Biologics 
Pharmaceutical companies need to mass-produce recombinant 
proteins64 so that they can ultimately purify these proteins to use as 
biologics.65  Generating a large quantity of protein is difficult 
because protein is produced within cells.66  To gain an appreciation 
of how challenging this entire process is, it is necessary to 
understand protein synthesis and purification. 
Proteins are large macromolecules that are produced within 
cells to perform specific functions and are the driving force of 
innovative biological research.67  When generating a large quantity 
of the desired protein, the targeted protein must be over-
expressed68 in a regulated environment to maximize the amount 
harvested.69  Researchers introduce recombinant coding DNA 
(cDNA) into either prokaryotes (cells without nuclei), or 
eukaryotes (nucleated cells).70  E. coli,71 for example, is a 
bacterium that can generate a large amount of protein in a short 
period of time, but lacks much of the internal machinery to 
generate more complex proteins (e.g. proteins modified by a fatty 
acid or sugar moiety).72  Many laboratories will first attempt to 
over-express proteins in E. coli because it is a simple and robust 
 
 64 Recombinant proteins are encoded by recombinant DNA or generated from a 
recombinant gene.  Free Online Medical Dictionary, Recombinant Protein, 
http://medical-dictionary.thefreedictionary.com/recombinant+protein (last visited Sept. 
23, 2009). 
 65 See CARL BRANDEN & JOHN TOOZE, INTRODUCTION TO PROTEIN STRUCTURE 375 (2d 
ed. 1999). 
 66 Id. 
 67 GARRETT & GRISHAM, supra note 48, at 107. 
 68 Over-expression is “excessive expression of a gene by producing too much of its 
effect or product.”  Merriam-Webster Online, Overexpression, http://www.merriam-
webster.com/medical/overexpress (last visited Sept. 23, 2009). 
 69 See BRANDEN & TOOZE, supra note 65. 
 70 ALBERTS ET AL., supra note 39, at 491–92. 
 71 Escherichia coli is a “gram negative bacterium widely used in microbiological and 
genetic research as well as in protein production.” Cytos Biotechnology, Glossary of 
Biological Terms, http://www.cytos.com/?id=197 (last visited Oct. 31, 2009). 
 72 See ALBERTS ET AL., supra note 39, at 491–92 (explaining how the normal 
replication mechanisms of a virus with recombinant DNA molecules can produce more 
than 1,012 identical virus DNA molecules in less than a day, thereby amplifying the 
amount of the inserted DNA fragment by the same factor). 
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process.73  However, many complex human proteins generated in 
E. coli will be inactive due to improper protein folding or the 
absence of protein translational modifications (which E. coli does 
not have the internal machinery to accomplish).74  Many proteins 
must be over-expressed instead in eukaryotic cells to be properly 
folded and modified.75  Thus, while scientists have the ability to 
introduce cDNA into cells for over-expression, the cells are 
ultimately in control and regulate the intracellular process.76 
The ability to purify over-expressed functional protein is at the 
heart of why generic biologics would be difficult to squeeze into 
the Hatch-Waxman Act, which provides companies the 
opportunity to produce generic drugs.77  A protein cannot be used 
as a biologic when it is still preserved within a cell.78  The 
purification process is crucial, as it washes away all other proteins 
and cellular debris.79  If the desired protein was not purified before 
 
 73 See Jeffrey G. Thomas & Francois Baneyx, Protein Misfolding and Inclusion Body 
Formation in Recombinant Escherichia Coli Cells Overexpressing Heat-Shock Proteins, 
271 J. BIOLOGICAL CHEMISTRY 11141, 11141 (1996) (“It is well established that the high 
level expression of recombinant proteins in Escherichia coli can result in the formation of 
insoluble aggregates known as inclusion bodies.  Since inclusion bodies consist mainly of 
the protein of interest and are easily isolated by centrifugation, their formation has often 
been exploited to simplify purification schemes.”). 
 74 See id. (“Molecular chaperones are a ubiquitous class of proteins that play an 
essential role in protein folding by helping other polypeptides reach a proper 
conformation or cellular location without becoming part of the final structure.”). 
 75 See Max-Planck-Innovation, Strategies to Enhance Protein Expression in Eukaryotic 
Cells, http://www.max-planck-innovation.de/share/technology/0301-3725-MSG-
ZE_DE.pdf?PHPSESSID=2b61508e0840eeaa5adf0eb9255e5a36 (last visited Oct. 31, 
2009). 
 76 See Bryan A. Liang, Regulating Follow-On Biologics, 44 HARV. J. ON LEGIS. 363, 
372 (2007) (listing the possible changes that may occur during a biologic manufacturing 
process). 
 77 Kelleher, supra note 43, at 249. 
 78 See Theresa Phillips, About.com, Methods for Protein Purification, 
http://biotech.about.com/od/protocols/a/ProteinPurify.htm (last visited Oct. 26, 2009) 
(“The degree of protein purity required depends on the intended use of the protein.  For 
some applications, a crude extract is sufficient.  However, for other uses, such as in foods 
and pharmaceuticals, a high level of purity is required.  In order to achieve this, several 
protein purification methods are typically used, in a series of purification steps.”). 
 79 AMERSHAM PHARMACIA BIOTECH, PROTEIN PURIFICATION HANDBOOK 7 (1999), 
available at http://www.biochem.uiowa.edu/donelson/Database%20items/protein_ 
purification_handbook.pdf [hereinafter PROTEIN PURIFICATION HANDBOOK] (“The 
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being injected into an ailing patient, the patient would suffer much 
more than be cured, as such alien proteins would be attacked by 
the body.80  The patient would act adversely to such an injection 
and, as a result, would develop an immediate and lasting immune 
response to all of the unrecognizable proteins introduced into his 
body.81  After all, consider that the over-expressed protein was 
generated from bacterial or eukaryotic (but non-patient) cells.  
Only protein that will not adversely affect the patient can be 
introduced into his body. 
As protein enrichment and protein purification are crucial to 
the generation of biological medicine, it is necessary to gain a solid 
understanding of each process.  Both the enrichment process and 
purification process, which vary significantly for each protein, are 
and will be treated by the pharmaceutical corporation as trade 
secrets.82  The methodology used to break open the cells, the 
solutions used to wash the proteins, and how to separate the 
desired protein from the cellular debris are all examples of how 
protein purification can be an unpredictable and a highly variable 
process.83  Because of this purification process and the uncertainty 
of the purity of the proteins, it would be difficult for companies to 
replicate brand-name biologics without the necessary trade 
 
development of techniques and methods for protein purification has been an essential 
prerequisite for many of the advancements made in biotechnology.”). 
 80 See Liang, supra note 76, at 375–77 (“[T]here is one central concern for [biologics] 
that is not present for chemical medicines: the potential for the product to induce an 
adverse immunologic reaction in a patient whose body sees the drug as a foreign invader, 
such as a virus or a bacterium. . . .  The immunogenicity of biologic drugs appears to be 
related to a broad array of factors, including the biologic’s structure, the patient’s genetic 
attributes, the type of biologic in question, impurities in the product, the route of 
administration, and the frequency of use.”). 
 81 Id. at 377 (“The human immune response to a biologic product is difficult to predict 
generally, and this is even more difficult in the face of changes to manufacturing 
processes.”). 
 82 See Corbitt, supra note 7, at 397–99; see also Kelleher, supra note 43, at 254. 
 83 PROTEIN PURIFICATION HANDBOOK, supra note 79, at 7 (“Proteins can even be 
produced in forms which facilitate their subsequent chromatographic purification.  
However, this has not removed all challenges.  Host contaminants are still present and 
problems related to solubility, structural integrity and biological activity can still exist.”). 
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secrets.84  Thus, even small changes in the process of generating a 
biologic “could result in a dramatically different final product.”85 
The most important aspect of this entire process is maintaining 
the activity of the protein.86  If the protein is over-expressed and 
purified, but is unable to function properly within a patient’s body 
upon injection, the pharmaceutical company has failed.87  Unlike 
drugs, which are small molecules that eventually break down over 
time, proteins may just not work at all.88  A drop in the activity of 
proteins can easily occur because of glitches in the purification 
process.89 
Researchers must monitor protein purity and activity because 
such differences can affect the body in a variety of ways.90  For 
example, if a patient’s normal physiological process cannot 
produce a functional protein, he absolutely requires a perfect 
biologic.  Furthermore, protein activity is crucial for dictating the 
dosage of the protein.91  For instance, if a brand-name biologic is 
twice as active as the generic, twice the amount of the generic 
biologic would have to be injected into the patient.92  Notably, the 
difference between dosages would suggest that the follow-on 
biologic is not a bioequivalent, but a biosimilar.93  Whether the 
 
 84 See infra notes 308–10 and accompanying text. 
 85 Gitter, supra note 30, at 561. 
 86 Protein Crystallography, Protein Purification in One Day: Introduction, 
http://proteincrystallography.org/protein-purification/introduction.php (last visited Oct. 
31, 2009) (stating that almost all proteins lose their activity and crystallization ability 
during manipulations).  
 87 See id. (“[F]or some proteins, even one extra day when they are being kept under 
conditions normally used for protein purification could be crucial in respect to their 
activity and crystallization ability.”).  
 88 See Liang, supra note 76, at 369 (explaining the composition of a biologic versus a 
drug). 
 89 See generally PROTEIN PURIFICATION HANDBOOK, supra note 79.  
 90 See generally id.  
 91 See ClinicalTrials.gov, A Phase I, Dose-Escalation Study to Assess the Safety and 
Biological Activity of Recombinant Human Interleukin-18, http://clinicaltrials.gov/ct2/ 
show/NCT00500058 (last visited Nov. 10, 2009), as an example of a biologic clinical 
trial attempting to identify a safe and effective dosage of the interleukin-18 drug, which is 
a protein in humans. 
 92 See id. 
 93 See Kelleher, supra note 43, at 254 (“When two chemically-synthesized drugs are 
proven bioequivalent, their safety and efficacy can be assumed because two identical 
drugs will consistently produce the same reactions.”). 
GOLDBERG_NOTE_123009_FINAL (DO NOT DELETE) 12/30/2009  10:48:32 AM 
340 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. [Vol. 20:327 
research and design teams can generate an equivalent from the 
beginning (over-expression) to the end (purification process) 
factors into the importance of trade secrets.94 
The FDA has previously relied on the Restatement of the 
Uniform Trade Secrets Act in defining property interests.95  Under 
the Restatement, “[a] trade secret may consist of any commercially 
valuable plan, formula, process, or device that is used for the 
making, preparing, compounding, or processing of trade 
commodities and that can be said to be the end product of either 
innovation or substantial effort.”96  As a result, trade secrets that 
pharmaceutical companies keep can and likely will translate into 
differences between biosimilars.97 
In summary: 
[M]anufacturing biologics can pose several 
problems, including: (1) the nature of manufacture; 
(2) the unlikelihood that a generic manufacturer 
could successfully reverse engineer the exact steps 
of synthesis used by the brand manufacturer; (3) the 
complexity and size of the molecules; (4) the 
possibility for serious and unpredictable side effects 
with even a small change; and (5) the difficulty of 
quality control, for even a meticulous replication of 
a biological compound is not identical to the 
developed compound it attempts to mimic.  Such 
drugs are thus termed “biosimilar,” since similarity 
to the biological molecule is all that can realistically 
be claimed.98 
 
 94 Corbitt, supra note 7, at 398. 
 95 Andrew Wasson, Taking Biologics for Granted? Takings, Trade Secrets, and Off 
Patent Biological Products, 2005 DUKE L. & TECH. REV. 4, 5. 
 96 21 C.F.R. § 20.61(a) (2009); see also Wasson, supra note 95, at 12 (quoting 21 
C.F.R. § 20.61(a)). 
 97 See Corbitt, supra note 7, at 398. 
 98 Id. at 378. 
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D. The Hatch-Waxman Act 
1. Overview 
Congress passed the Hatch-Waxman Act99 in 1984 to balance 
the competing interests of generic pharmaceutical companies and 
brand-name pharmaceutical companies.100  To promote 
competition with brand-name drug manufacturers, generic 
pharmaceutical companies need to gain immediate approval for 
selling the follow-on drug.101  Thus, these companies require a 
reduced process for drug approval and an accelerated patent 
litigation process.102  Meanwhile, brand-name pharmaceutical 
companies must preserve their profit margins to be able to afford 
research and development of drugs.103 
To balance the competing interests of brand-name and generic 
pharmaceutical companies, the Hatch-Waxman Act permits the 
filing and evaluation of “Abbreviated New Drug Applications” 
(“ANDA”s).104  By securing an ANDA, a company is permitted to 
generate a generic version of a patented drug.105  The company 
must prove that the drug is safe and effective to secure an 
ANDA;106 to do this the applicant merely must submit 
experimental proof that the brand-name drug and the replicated 
generic are equivalent.107 
An ANDA certifies one of four possibilities: “1) the drug has 
not been patented; 2) the patent has expired; 3) the generic will not 
be sold on the market until after the date which the patent will 
expire; and 4) the patent is not infringed or is invalid.”108  If the 
ANDA is filed under the circumstance that the patent is not 
 
 99 See 98 Stat. 1585 (1984) (codified as amended at 21 U.S.C. § 355 and 35 U.S.C. § 
271(e) (2006)). 
 100 Id. 
 101 Corbitt, supra note 7, at 372. 
 102 Id. 
 103 Id. 
 104 Id. 
 105 Id. 
 106 Id. 
 107 Id. 
 108 Gerald J. Mossinghoff, Overview of the Hatch-Waxman Act and Its Impact on the 
Drug Development Process, 54 FOOD & DRUG L.J. 187, 189 (1999). 
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infringed or is invalid, the applicant must give notice to the patent 
holder that it has filed an ANDA.109  The applicant notifies the 
patent holder under these conditions because filing the ANDA 
constitutes literal infringement.110  Further, the ANDA is 
processed, but final approval is not granted during the thirty month 
stay in order for both parties to litigate the allegation of invalidity 
and/or non-infringement.111 
The patent-holder has forty-five days to file suit for 
infringement in order to obtain the benefit of the thirty month stay 
of approval.112  If the patent-holder chooses to file suit, the FDA 
will not grant final approval of the ANDA for thirty months, 
permitting litigation between the parties.113  The brand-name 
pharmaceutical company could win patent term extensions and 
market exclusivity provisions,114 while the generic company could 
win 180 days of market exclusivity for the generic equivalent of 
the drug.115  Thus, while ANDAs give the generic companies the 
ability to quickly begin marketing and selling a bioequivalent 
product,116 the brand-name companies enjoy the notice 
requirement with the possibilities of term extensions and market 
exclusivity.117 
2. Hatch-Waxman Act Application to Generic Biologics 
Congress has tried to apply the Hatch-Waxman Act to 
biologics.118  Biologics are complex proteins that are manufactured 
within cells (in vivo), not in test tubes (in vitro).119  Currently, 
however, some of the smaller biological matter is classified as 
 
 109 Id. at 190. 
 110 Corbitt, supra note 7, at 373. 
 111 Id. 
 112 Id. 
 113 Id. 
 114 Id. 
 115 Id. 
 116 Id. 
 117 Id. 
 118 See H.R. 5629, 110th Cong. (2008); S. 1695, 110th Cong. (2007); H.R. 1956, 110th 
Cong. (2007); H.R. 1038, 110th Cong. (2007). 
 119 Liang, supra note 76, at 369 (describing how biologics production introduces DNA 
into a cell line); see also ALBERTS ET AL., supra note 39, at 472 (explaining in vivo and in 
vitro procedures). 
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“drugs” to permit Hatch-Waxman application.120  Two sections of 
the Hatch-Waxman Act are utilized for small-molecule drugs: 
section 505(j) and section 505(b)(2) of the Food, Drug, and 
Cosmetic Act (“FDCA”).121 
The more prevalently used section of the Hatch-Waxman Act 
for small-molecule drugs is section 505(j) of the FDCA, which 
permits an applicant to file an ANDA.122  This section established 
the ANDA approval process, allowing cheaper generic forms of 
approved innovator drugs to be approved and brought on the 
market:123 
An ANDA applicant must include in the ANDA 
a patent certification described in section 
505(j)(2)(a)(vii) of the Act.  The certification must 
make one of the following statements: (I) no patent 
information on the drug product that is the subject 
of the ANDA has been submitted to [the] FDA; (II) 
that such patent has expired; (III) the date on which 
such patent expires; or (IV) that such patent is 
invalid or will not be infringed by the manufacture, 
use or sale of the drug product for which the ANDA 
is submitted.  This last certification is known as a 
paragraph IV certification.  A notice of the 
paragraph IV certification must be provided to each 
owner of the patent that is the subject of the 
certification and to the holder of the approved NDA 
to which the ANDA refers.  The submission of an 
ANDA for a drug product that is claimed in a patent 
is an infringing act if the drug product that is the 
subject of the ANDA is intended to be marketed 
before the expiration of the patent and, therefore, 
 
 120 Liang, supra note 76, at 390. 
 121 Federal Food, Drug, and Cosmetic Act § 505(b)(2), 21 U.S.C. § 355(j) (2006). 
 122 Kelleher, supra note 43, at 249. 
 123 See U.S. DEP’T OF HEALTH & HUMAN SERVS., FOOD & DRUG ADMIN., CTR. FOR 
DRUG EVALUATION & RESEARCH, GUIDANCE FOR INDUSTRY, 180-DAY GENERIC DRUG 
EXCLUSIVITY UNDER THE HATCH-WAXMAN AMENDMENTS TO THE FEDERAL FOOD, DRUG, 
AND COSMETIC ACT (1998), available at http://www.fda.gov/downloads/Drugs/Guidance 
ComplianceRegulatoryInformation/Guidances/ucm079342.pdf. 
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may be the basis for patent infringement 
litigation.124 
Section 505(j)(5)(B)(iv) further provides an incentive for 
generic manufacturers to file paragraph IV certifications.  This 
section states that, in certain circumstances, 
an ANDA applicant whose ANDA contains a 
paragraph IV certification is protected from 
competition from subsequent generic versions of the 
same drug product for 180 days after either the first 
marketing of the first applicant’s drug or a decision 
of a court holding the patent that is the subject of 
the paragraph IV certification to be invalid or not 
infringed.125 
Section 505(j) reflects Congress’ intentions to balance 
encouraging innovation with the need to provide cheaper 
alternatives to the American public.126 
The less utilized section of the Hatch-Waxman Act is section 
505(b)(2).  The FDA has only been able to approve biological 
therapies using section 505(b)(2) when these compounds are 
classified as drugs, despite being biologics.127 
Created in 1984 as part of the Hatch-Waxman 
Amendments to the Federal Food, Drug, and 
Cosmetic Act, the 505(b)(2) application is intended 
to encourage sponsors to develop innovative 
medicines using currently available products.  
According to Section 505(b)(2) guidelines, an NDA 
approval can be obtained for a new drug without 
conducting the full complement of safety and 
 
 124 Id. at 3–4. 
 125 Id. at 4. 
 126 Follow-on Protein Products: Hearing on Safe and Affordable Biotech Drugs Before 
H. Comm. on Oversight and Government Reform, 110th Cong. (2007), available at 
http://www.fda.gov/NewsEvents/Testimony/ucm154070.htm (statement of Janet 
Woodcock, M.D., Deputy Commissioner and Chief Medical Officer, Food and Drug 
Administration). 
 127 Nathan A. Beaver & Kelly A. Hoffman, Final Word: Omnitrope’s Approval: What 
Does it Mean for Other Generics?, BIOPHARM INT’L, Aug. 1, 2006, http://biopharm 
international.findpharma.com/biopharm/article/articleDetail.jsp?id=361018. 
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efficacy trials and without a “right of reference” 
from the original applicant. . . . [505(b)(2)] proposes 
a limited change to a previously approved product, 
but demonstrates the required safety and efficacy of 
the change.128 
Some examples of generic drugs that the FDA has approved 
using this section are recombinant follitropin beta (Follistim®), 
recombinant human glucogon (GlucaGen®), and human growth 
hormone (Omnitrope®).129  Section 505(b)(2) is essentially a 
hybrid between a NDA and an ANDA, as applicants may rely on 
the experimentation conducted by a third party, including the 
innovative manufacturer, to show the safety of their own 
products.130  The applicant need not perform many of the trials 
himself if he proves the “relevance and applicability” of any 
previous clinical findings.131  Thus, the applicant can evade much 
of the cost associated with seeking FDA approval of a new drug. 
The FDA is hesitant to approve more complex biological 
therapies under section 505(b)(2).132  While the FDA has approved 
biologic drugs under section 505(b)(2), such as menotropins, 
glucagon, and calcitonin, generally the FDA maintains that follow-
on biologics “present unique and difficult questions that will be 
addressed in a timely manner.”133  Therefore, the use of this 
pathway within the Hatch-Waxman Act is limited.  Use of this 
provision would require biological substances to gain approval as 
new drugs under the FDCA or the Hatch-Waxman provision, as 
approved under the PHSA.134  However, this is unlikely, as 
Congress is not considering any legislation that would clarify or 
expand FDA authority to regulate and approve generic 
 
 128 Kenneth V. Phelps, The 505(b)(2) Alternative—An NDA That Saves Time and 
Money, DIA FORUM, Mar. 2005, available at http://www.camargopharma.com/Userfiles/ 
Docs/camargo-505b2.pdf. 
 129 See Liang, supra note 76, at 393–97. 
 130 Kelleher, supra note 43, at 250. 
 131 Id. 
 132 Id. at 251. 
 133 Kenneth D. Growth, Biosimilars Shake Up the Biologics Market, GENETIC 
ENGINEERING NEWS, Dec. 1, 2005, at 48, available at http://www.genengnews.com/ 
articles/chitem.aspx?aid=1159&chid=0; see also Beaver & Hoffman, supra note 127. 
 134 Beaver & Hoffman, supra note 127. 
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biologics.”135  Thus, section 505(b)(2) is not a practical pathway to 
pursue to gain generic approval of biological material as the FDA 
has expressed discomfort in using this pathway for this exact 
reason.136 
3. The Uncertain Future of the Hatch-Waxman Act 
Since there has not been a uniform approval process for 
producing generic biologics under existing United States law, 
Congress attempted to enact the Biologics Act of 2007.137  At the 
Biosimilars Conference in 2007, Representative Henry Waxman 
stated that biotechnology drugs embody the future of medicine, as 
there were almost 500 new such drugs in development.138  The 
FDA has not regulated the majority of new biologics as new drugs 
under the FDCA, but instead under the PHSA.139  Thus, an 
applicant would file a biologics application (“BLA”), but not a 
NDA.140  A BLA confirms the safety and purity of the drug.141  
Companies, however, may not file a BLA for most biosimilars due 
to current practice.142  The FDA has only approved the smaller, 
simpler biological “drugs” for manufacture through an NDA, such 
as insulin and human growth hormone (“HGH”).143  Therefore, 
companies may manufacture the drugs generically through an 
ANDA.144  It is not clear, however, why few biologically based 
drugs are permitted through this process.145  There are also 
currently no guidelines to lead manufacturers in filing a NDA or a 
BLA application.146 
There is still no clear process for approval for generic 
biologics.  An illustration of how the absence of such guidelines 
 
 135 Id. 
 136 Id. 
 137 See Congressman Henry A. Waxman, Remarks at Biosimilars 2007 Conference 
(Sept. 24, 2007), available at http://www.biosimilarstoday.com/Waxman.pdf. 
 138 Id. 
 139 Kelleher, supra note 43, at 251. 
 140 Liang, supra note 76, at 392. 
 141 Id. 
 142 Id. 
 143 See id. at 390–97. 
 144 See id. 
 145 Id. 
 146 Liang, supra note 76, at 392. 
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affects competition is the court decision in Sandoz, Inc. v. 
Leavitt.147  Sandoz, Inc. (“Sandoz”) was a generic drug subsidiary 
of Novartis, one of the largest multi-national pharmaceutical 
companies.148  Sandoz sued Michael Leavitt, the Secretary of 
Health and Human Services, and Andrew Von Eschenback, the 
acting Commissioner of the FDA, because Sandoz wanted to sell 
Omnitrope.149  Omnitrope was going to be a follow-on drug 
comparable to Genotropin, a substitute for HGH.150  Low levels of 
HGH cause various growth disorders and Genotropin could 
alleviate this condition.151  To market and sell Omnitrope, Sandoz 
submitted an ANDA to the FDA in 2003 and stated that this 
follow-on drug was safe and identical to the pioneer drug, 
Genotropin.152  The FDA deferred its decision and did not act 
within 180 days; therefore, Sandoz filed suit.153  At the time, like 
today, there was still no clear process for approval: 
It is true that today the FDA regulates most 
biopharmaceuticals under the Public Health Service 
Act, which as previously discussed, is not part of 
the Hatch-Waxman regime.  But the Public Health 
Service Act has for many years contained a 
provision stating that nothing in that Act shall affect 
the FDA’s jurisdiction under the FDCA, and it is 
clear that FDA could regulate all 
biopharmaceuticals under the FDCA, as it had 
chosen to do for insulin and human growth 
hormone.154 
The Sandoz court sidestepped the issue of defining a process 
for approving the production of generic biologics.155  It directed 
 
 147 427 F. Supp. 2d 29 (D.D.C. 2006). 
 148 Id. at 31–32. 
 149 Id. at 32. 
 150 Id. 
 151 Id. at 31. 
 152 Id. at 32. 
 153 Id. 
 154 The Law of Biologic Medicine: Hearing Before the S. Comm. on the Judiciary, 
108th Cong. (2004) (statement of William Schultz, Partner at Zuckerman Spaeder, LLP), 
available at http://judiciary.senate.gov/hearings/testimony.cfm?id=1239&wit_id=3627. 
 155 See Sandoz, 427 F. Supp. 2d at 41. 
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the FDA to immediately decide whether to approve the license of 
Omnitrope.156  The FDA then approved Omnitrope as a “follow-on 
protein product” but not as a biologic.157  The FDA further 
expressed that the approval of Omnitrope did not carve out a 
guaranteed pathway to gain approval of other biosimilars.158  Some 
have suggested that Congress should take legislative action in 
response to the district court decision in Sandoz.159 
In addition, it may be necessary to create legislation to clarify 
the FDA’s role and responsibilities in the approval process.160  
There has been an increased need to have a process promptly put in 
place because the first generation of biologic therapies will expire 
in 2015.161  The public need for competition will not be met if 
there is no expedited pathway for approval of generic biologics.162  
Importantly, applicants attempting to gain approval for the 
manufacture of generic biologics must also submit: 1) analytical 
studies demonstrating biosimilarity, 2) animal studies, and 3) a 
minimum of one clinical study that demonstrates safety, purity, 
and potency.163  Since analytical studies, animal studies, and 
clinical studies take years to perform, competition between 
innovative and follow-on biologics could be compromised. 
Additionally, Representative Waxman has concerns regarding 
the length of brand-name exclusivity.  Representative Waxman 
argues that a reasonable term of exclusivity is “not one that is so 
long that it would rob the American people of the cost-saving 
appropriate generic competition brings,”164 and that such a term 
should be less than ten years.165  While it is important that generic 
biologics must become available to drive costs down and facilitate 
competition, incentives for brand-name pharmaceuticals must 
 
 156 Id. 
 157 Kelleher, supra note 43, at 251. 
 158 Id. at 251–52. 
 159 Id. at 252. 
 160 Corbitt, supra note 7, at 381. 
 161 Id. 
 162 See Kelleher, supra note 43, at 252. 
 163 See Liang, supra note 76, at 384–85. 
 164 See Waxman, supra note 137. 
 165 See id. 
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remain high.166  Those against the Waxman Bill believe that if it 
becomes easier for generic biologics to compete with brand-name 
biologics and/or the term of exclusivity is significantly 
abbreviated, innovative pharmaceutical companies will lose 
incentive to continue current research and development.167 
Despite Representative Waxman’s optimism for the future of 
generic biologics, many economists challenge the idea that access 
to follow-on biologics will decrease prices for consumers.168  
Economists estimate that the cost of producing and experimenting 
upon generic biologics will be a great deal higher than with small-
molecule drugs.169  “The cost associated with getting a biogeneric 
to market could be tens of millions of dollars, as compared to a 
couple of million dollars for traditional generics.”170  Additionally, 
biologics have more specific, targeted activities compared to small 
molecule drugs.171  This translates to smaller markets that are 
interested in investing in such therapies.172  Thus, one can easily 
argue that very few companies are likely to prosper in generating 
follow-on biologics.173 
E. What Americans Can Learn from the EU 
On the other hand, the European Union (“EU”) has a system 
that permits generic biologic approval and has saved several billion 
dollars from the market entry of only a few products.174  The EU 
established a regulatory approval process for biosimilar medicines 
 
 166 Donald Zuhn, BIO CEO Makes Case for 12-Year Data Exclusivity Period, PATENT 
DOCS, Aug. 16, 2009, http://www.patentdocs.org/2009/08/bio-ceo-makes-case-for-
12year-data-exclusivity-period.html. 
 167 See id. 
 168 See Suzanne M. Sensabaugh, Biological Generics: A Business Case, 4 J. GENERIC 
MED. 186, 188–89 (2007). 
 169 See id. at 189. 
 170 Kelleher, supra note 43, at 253. 
 171 See Liang, supra note 76, at 369. 
 172 See generally U.S. CONG. BUDGET OFFICE, HOW INCREASED COMPETITION FROM 
GENERIC DRUGS HAS AFFECTED PRICES AND RETURNS IN THE PHARMACEUTICAL INDUSTRY 
13–35 (1998), available at http://www.cbo.gov/ftpdocs/6xx/doc655/pharm.pdf.   
 173 See generally id.  
 174 Kathleen Jaeger, GPhA President and CEO, GPhA Speech at Windhover FDA/CMS 
Summit (Dec. 5, 2006), available at http://www.gphaonline.org/resources/2006/12/04/ 
gpha-speech-windhover-fdacms-summit. 
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in Europe in 2006, when the European Commission approved the 
first biosimilar medicines.175 
All biotechnology medicines, including 
biosimilar biotechnology-derived medicines, are or 
will be assessed by the European Medicines Agency 
in London (EMEA), which constitutes the scientific 
body of the European Commission responsible for 
the evaluation of medicines.  They are approved by 
the European Commission based on the positive 
scientific opinion issued by the EMEA. 
When the EMEA assesses data for a biosimilar 
medicine, the scientific principles for ensuring 
product quality, safety and efficacy are identical to 
those applied to the originator/brand reference 
medicine with which comparability is demonstrated. 
In addition to the quality data required for all 
biotechnology products, the companies involved in 
the developing biosimilar medicines must 
additionally submit “comparability data.” Indeed, 
manufacturers must characterize, in parallel, both 
their biosimilar product and the originator reference 
product.  They must demonstrate, with a high 
degree of certainty, that the quality of the biosimilar 
medicine is comparable to the originator/reference 
medicinal product.  A comparability programme is 
clearly defined and agreed upon in advance with the 
EMEA, who defines the set of non-clinical and 
clinical data that are necessary to sufficiently 
demonstrate biosimilarity.  The extent of this data 
varies according to the type and complexity of the 
medicine involved.  Each individual biosimilar 
medicine is assessed on a case-by-case basis.176 
In addition, the EU states that patients can be assured of safety 
because of two systems: regulations require that the European 
 
 175 Liang, supra note 76, at 399–400. 
 176 European Generic Medicines Association, FAQ on Biosimilar Medicines, 
http://www.egagenerics.com/doc/FAQ_biosimilars.pdf (last visited Aug. 27, 2009). 
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pharmaceutical companies monitor the use and effects of their 
medicines and provide that a Risk Management Plan is required for 
each new biosimilar medicine.177 
The EU notes that “[t]he price differential between a reference 
product and a biosimilar medicine will depend on the relative 
development costs.”178  While the EU is optimistic about the 
relative savings courtesy of biosimilars, development costs may 
compromise savings.179 
F. The Public Health Service Act 
1. Biologics in the Eyes of the Public Health Service Act 
A biological product, as defined by the PHSA, is “a virus, 
therapeutic serum, toxin, antitoxin, vaccine, blood, blood 
component or derivative, allergenic product, or analogous product, 
or arsphenamine or derivative of arsphenamine (or any other 
trivalent organic arsenic compound), applicable to the prevention, 
treatment, or cure of a disease or condition of human beings.”180  
Some examples of biologics include some vaccines, and 
monoclonal antibodies, which can aid in the treatment of cancer, 
anemia, hepatitis, and multiple sclerosis.181 
Biologic product sales are continually increasing, with 
American product sales jumping from $32.8 billion to $56 billion 
from 2005 to 2006.182  Global sales are expected to reach $105 
billion by 2010.183  In the past ten years, the patents of more than a 
dozen high-profit biologics have expired, creating $11.5 billion in 
combined annual sales of off-patent biologics.184 
 
 177 Id. 
 178 Id. 
 179 See id. 
 180 42 U.S.C. § 262(i) (2006). 
 181 Kelleher, supra note 43, at 247. 
 182 Gregory Roumeliotis, FDA Under Pressure to ‘Open the Floodgates’ for 
Biogenerics, IN-PHARMA TECHNOLOGIST.COM, Aug. 17, 2006, http://www.in-
pharmatechnologist.com/news/ng.asp?n=69925-fda-biogenerics-insulin-hgh-omnitrope. 
 183 Kelleher, supra note 43, at 247. 
 184 Meredith Wadman, Copycats Gear Up to Dog Biotech Brands, NATURE, Oct. 5, 
2006, http://www.nature.com/nature/journal/v443/n7111/full/443496a.html. 
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With a few exceptions, generic biologics have not been able to 
enter the market due to the current regulatory scheme.185  One 
method of approving generic biologics is by enlarging the Hatch-
Waxman Act.186  However, because biological products are highly 
complex and vary vastly from generic drugs, a new regulatory 
scheme would need to be put in place for generic biologics to 
compete.187 
2. Comparison to the Food, Drug, and Cosmetic Act 
The regulation of biological products is unique from small-
molecule drugs.  Most biologics are not regulated as drugs under 
the FDCA but are instead licensed under section 351 of the PHSA 
and then evaluated by the Center of Biologics Evaluation and 
Research (“CBER”).188  Under the PHSA, each biologic must 
secure a license, which validates the product as safe and pure.189  
The PHSA does not contain a provision for follow-on biologic 
approval.190 
Whereas the PHSA ostensibly applies to most or all biologics, 
the FDCA, on the other hand, has decided to regulate a small 
number of biologics, such as insulin and HGH.191  Despite 
providing no clear explanation as to why only these biologics are 
regulated by the FDCA, such regulation falls under the FDCA.192  
The FDCA’s definition of a “drug” includes “articles intended for 
use in the diagnosis, cure, mitigation, treatment, or prevention of 
disease in man.”193  Thus, this language suggests that the FDCA’s 
regulation encompasses biological materials as well as drugs.194 
 
 185 Liang, supra note 76, at 409. 
 186 Supra note 2. 
 187 Wasson, supra note 95, at 3. 
 188 Id. at 4. 
 189 Id. 
 190 Id. 
 191 Kelleher, supra note 43, at 249. 
 192 Wasson, supra note 95, at 9. 
 193 21 U.S.C. § 321(g)(1)(B) (2006). 
 194 Id. 
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G. A Tale of Two Bills: The Next Chapter 
President Obama’s 2010 budget proposal creates an 
abbreviated pathway for follow-on biologics.195  The 111th 
Congress will consider two competing pieces of legislation: House 
Bill 1427 (the Waxman Bill)196 and House Bill 1548 (the Eshoo 
Bill).197  The Waxman Bill and the Eshoo Bill would amend the 
PHSA to add a subsection permitting follow-on biologics to enter 
the market.198  The two issues that are at the heart of these bills are: 
1) the term of exclusivity of the pioneer company, and 2) the 
evidence required to show that the generic biologic is biosimilar to 
the pioneer biologic.199  Congress considered similar legislation in 
past years, but the current presidential and bipartisan support will 
likely lead to enactment of a generic approval.200  While the 
Waxman Bill favors quicker public access to generic biologics,201 
the Eshoo Bill encourages more testing before approving the 
biologic.202 
Generic manufacturers support the Waxman Bill, while 
innovative manufacturers favor the Eshoo Bill.203  Both the 
Waxman Bill and the Eshoo Bill will permit the FDA to license 
biologics deemed “biosimilar.”204  The Waxman Bill defines 
“biosimilar” by stating that “no clinically meaningful differences 
between the biological product [follow-on biologic] and the 
reference product [innovative biologic] would be expected in terms 
of the safety, purity, and potency if treatment were to be initiated 
 
 195 See Barbara Carter, Congress Answers the Call to Permit Generic Versions of 
Biologic Drugs, SUNSTEIN INTELL. PROP. UPDATE, Mar. 2009, http://www.bromsun.com/ 
publications-news/news-letters/2009/03/200903biologics.html. 
 196 H.R. 1427, 111th Cong. (2009). 
 197 H.R. 1548, 111th Cong. (2009). 
 198 Rep. Eshoo Proposes Draft Biogenerics Bill, FDA Law Blog, http://www.fdalaw 
blog.net/fda_law_blog_hyman_phelps/2008/02/a-peek-inside-p.html (Feb. 18, 2008, 
07:26 EST). 
 199 H.R. 1548, 111th Cong. (2009); see also FDA Law Blog, supra note 198. 
 200 Ramon Tabtiang et al., Congress Considers Competing Biosimilar Legislation, FISH 
NEWS, http://fr.com/news/articledetail.cfm?articeid=939. 
 201 Carter, supra note 195. 
 202 Id. 
 203 Tabtiang et al., supra note 200. 
 204 Id. 
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with the biological product instead of the reference product.”205  
Both bills require generic biologic applicants to submit data 
indicating that any biogeneric has highly similar molecular 
structure to the reference product.206 
A key assertion in the Eshoo Bill is that a generic biologic is 
not identical to the innovative biologic.207  The Eshoo Bill states 
that a generic biologic can never be substituted for an innovative, 
pioneer biologic.208  Additionally, the Eshoo Bill requires 
analytical and animal studies to show that the follow-on biologic is 
highly similar to the innovative biologic.209  This bill will permit 
the FDA to waive these tests, but only after requesting and 
considering public comments regarding the balancing of price 
competition and safety.210 
The Waxman Bill, on the other hand, proposes comparatively 
lenient standards for determining equivalence between pioneer and 
follow-on biologics.211  This bill proposes that a follow-on biologic 
only have “highly similar molecular structural features” or have 
“interchangeability with” the pioneer drug.212  Generic drug 
companies can easily satisfy this requirement, as these companies 
may use the clinical studies and efficacy tests initially performed 
by the pioneer company.213  Thus, this bill does not require the 
pharmaceutical company to perform further testing. 214 
The Eshoo Bill and the Waxman Bill also differ with respect to 
exclusivity.  The Eshoo Bill allows for twelve years of data 
exclusivity and provides up to two more years for a new use 
approved for the pioneer biologics.215  However, the Waxman Bill 
suggests a short exclusivity period of five and a half years, and 
 
 205 H.R. 1427, 111th Cong. § 3(k)(1) (2009). 
 206 Tabtiang et al., supra note 200. 
 207 H.R. 1548, 111th Cong. (2009). 
 208 Id. 
 209 Id. 
 210 Id. 
 211 Carter, supra note 195. 
 212 Id. 
 213 Id. 
 214 Id. 
 215 H.R. 1548, 111th Cong. (2009). 
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three more years of data exclusivity for new uses and formulations 
of the innovative biologic.216 
II. CARRY THAT WEIGHT: HOW PENDING LEGISLATION ALTERS 
THE CURRENT MODEL 
There are great concerns about how amendments to the Hatch-
Waxman Act, in the form of the Waxman and Eshoo Bills, may 
change the face of patent law.  A patent requires the inventor to 
release information that would allow a person having ordinary skill 
in the art to recreate the invention completely.217  However, it is 
inherent in the definition of a “biologic” that such molecules are 
much more difficult to recreate than small molecule drugs.218  
Biologics, which researchers and companies grow and harvest in 
vivo, present many hurdles that make them difficult to recreate in 
the form of generics.219  Because it is so difficult to recreate 
biologics, the patent requirement of enablement220 is trickier to 
satisfy and makes it more difficult to generate generic biologics.221  
Despite this strain on the patent system, there is an enormous and 
still growing need for generic biologics.222  The mounting 
necessity for generic biologics puts a strain on two opposing needs: 
1) the need for generic biologics to slash costs,223 and 2) the 
requirement that all biologic medication being sold is 
bioequivalent to the innovative biologic and is safe to use.224 
 
 216 H.R. 1427, 111th Cong. (2009). 
 217 Corbitt, supra note 7, at 397. 
 218 See id. at 377. 
 219 Id. at 378. 
 220 35 U.S.C. § 112 (2006) (stating that the specification must describe how to make 
and use the invention to one skilled in the art); see also United States Patent and 
Trademark Office, 2164 The Enablement Requirement [R-2]—2100 Patentability, 
http://www.uspto.gov/web/offices/pac/mpep/documents/2100_2164.htm (last visited Oct. 
16, 2009). 
 221 See Corbitt, supra note 7, at 367–68. 
 222 Id. at 369. 
 223 Id. 
 224 Id. at 372. 
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A. The Intersection Between Patent Law and Biologics 
Because of the chemical differences between simple small-
molecule drugs and complex biological compounds, several 
problems arise when trying to apply the current Hatch-Waxman 
provisions to biological compounds.225  Biologic compounds are 
larger and more complex than small-molecule drugs, requiring a 
more sophisticated and regulated methodology of production.226  
Because of the intricacies in producing sensitive biologics, small 
changes in production could have severe and far-reaching 
consequences in a patient’s health.227 
Besides the health concerns associated with taking generic 
forms of biologic compounds, there are general concerns about the 
impact of biologic legislation on United States patent law.228  
“First, if it is impossible to synthesize an identical compound the 
effect could be to preclude patentability on the grounds of 
‘enablement.’”229  The patent-holders, the brand-name 
pharmaceutical companies, would walk a thin line if required to 
argue the conflicting ideas that their product is enabled and yet it is 
impossible to replicate due to the nature of production.230  Second, 
patentability is questioned because many biologics are compounds 
already produced, in vivo, in every healthy human being.231  Thus, 
while the process of generating large quantities of any biologic can 
be novel, the biological compound may not meet the patentability 
requirement of novelty.232  The legislators must consider these 
problems before they assume that the parameters set in place by 
the Hatch-Waxman Act, written for competition of small-molecule 
drugs,233 will directly apply to biologics. 
In addition to enablement for patent eligibility, one must also 
show novelty.  To be novel, an invention must be new, unknown to 
 
 225 Id. at 397. 
 226 See supra notes 41–59. 
 227 Corbitt, supra note 7, at 366–67. 
 228 Id. at 367. 
 229 Id. 
 230 Id. at 367–68. 
 231 Id. at 368. 
 232 Id. 
 233 Id. 
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the public, and not published (or described in a pending U.S. patent 
application) anywhere.234  Diamond v. Chakrabarty, a landmark 
Supreme Court case, allowed biotechnology innovation to fall 
within the scope of statutorily patentable inventions.235  The Court 
stated that a living organism can be patentable as long as it was not 
naturally-occurring.236  Thus, discoverable matter is not patentable, 
while inventions are patentable.237  This principle extends to the 
biological therapies that would be encompassed by the Biologics 
Act, if the legislation passes.  For example, a purified protein is 
patentable because there is a difference between pure and impure 
materials.238  Thus, a patentable innovation can be the actual 
purification process, despite the fact that the product itself is 
naturally-occurring. 
B. Why Push for Generic Biologics? 
As discussed earlier,239 Americans are deeply concerned about 
the cost of drugs,240 and they have therefore embraced generic 
alternatives.  Generic alternatives have also made a lasting 
impression on the pharmaceutical industry.241  Ten years after the 
Hatch-Waxman Act was passed in 1994, Americans saved between 
$8 and $10 billion in drug stores by purchasing generic drugs 
instead of brand-name drugs.242  Americans have shown the 
pharmaceutical companies that they want to decide between a 
brand-name form of a small-molecule drug and the generic 
equivalent, and that they want to save money.243  This financial 
need for cheaper drugs translates into the public wanting and 
needing competition between brand-name and generic biologics.244  
 
 234 35 U.S.C. § 102 (2006). 
 235 Diamond v. Chakrabarty, 447 U.S. 303, 316 (1980) (“A rule that unanticipated 
inventions are without protection would conflict with the core concept of the patent law 
that anticipation undermines patentability.”). 
 236 See id at 317. 
 237 Id. at 309. 
 238 In re Bergstrom, 427 F.2d 1394, 1402 (C.C.P.A. 1970). 
 239 See supra notes 1–8 and accompanying text. 
 240 See supra note 1 and accompanying text. 
 241 See U.S. CONG. BUDGET OFFICE, supra note 172. 
 242 Id. at ix. 
 243 See id. 
 244 Id. at x. 
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By facilitating price competition through passing new legislation, 
for example via the Eshoo Bill or Waxman Bill, more follow-on 
biologics would be available to patients.245 
Generic drugs, though, have hampered the innovative 
pharmaceutical industry’s ability to recover investment costs.246  
Investment in research and development has increased from 14.7%  
to 19.4%, while sales rose from $17 billion to $57 billion between 
1983 and 1995.247  These ascending numbers, however, hardly 
account for innovative pharmaceutical companies branching out in 
research and development more rapidly, resulting from generic 
pharmaceutical companies pushing to sell on the market.248  
Follow-on drugs, also called generic small-molecule drugs, have 
surely cut into brand-name drug revenue.249 
C. No Consensus on Exclusivity 
Each of the two pending bills appeal to either the innovative 
pharmaceutical industry or the generic pharmaceutical industry.  
Innovative and generic pharmaceutical companies have agreed that 
there is a need for follow-on biologics; however, they disagree 
about the exclusivity period for brand-name drugs.250  Generic 
companies favor shorter periods of exclusivity, approximately 
seven years, while innovative pharmaceutical companies support 
bills providing twelve to fourteen years of exclusivity.251 
Five congressional bills introduced in 2007 and 2008 began a 
thoughtful discussion regarding generic biologics, but they 
ultimately did not pass.252  These bills would have amended 
 
 245 Id. 
 246 Id. at xiii. 
 247 Id. at xv. 
 248 See id. 
 249 Associated Press, Brand Name Drugs Going Generic, NBC ACTION NEWS.COM, 
Dec. 10, 2008, http://www.nbcactionnews.com/mostpopular/story/Brand-Name-Drugs-
Going-Generic/j5hxwTekPkSZG-NWWQ31MA.cspx.  In the United States, generic 
prescription drugs cost approximately 1/3 less than brand name drugs. Id. 
 250 See Pollack, supra note 1. 
 251 Donald Zuhn, Top Stories of 2008: #9 to #6, PATENT DOCS, Jan. 4, 2009, 
http://www.patentdocs.org/2009/01/top-stories-of-2008-9-to-6.html. 
 252 H.R. 5629, 110th Cong. (2008); S. 1695, 110th Cong. (2007); S. 1505, 110th Cong. 
(2007); H.R. 1956, 110th Cong. (2007); H.R. 1038, 110th Cong. (2007). 
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section 351 of the PHSA to establish a route for approval of an 
abbreviated biological product application for products that contain 
the same or similar active ingredients as previously licensed 
biological products.253 
The Access to Life-Saving Medicine Act, House Bill 1038,254 
was introduced February 14, 2007, by Representative Henry 
Waxman and stipulated that the biosimilar and reference must have 
the same mechanism of action for the same condition of use,255 but 
did not mention the provisions for data and market exclusivity.256  
The Patent Protection and Innovative Biologic Medicines Act, 
House Bill 1956, was introduced April 19, 2007, by Representative 
Jay Inslee, and stated that biosimilar and reference material must 
merely show comparative results in health-related assays for the 
same dosage.257  House Bill 1956 took a bold move and provided 
twelve years of data exclusivity and just two years of market 
exclusivity.258  The Biologics Price Competition Innovation Act, 
Senate Bill 1695, was introduced on June 26, 2007, as a bipartisan 
effort guided by Senators Kennedy and Hatch, and suggested that 
the biosimilar and reference must have the identical route of 
administration, dosage form, and strength, as well as utilize the 
same mechanism of action for the same condition of use.259  The 
Biologics Price Competition Innovation Act, Senate Bill 1695, 
additionally called for four years of data exclusivity and eight 
years of market exclusivity.260  House Bill 5629, the Pathway for 
Biosimilars Act, would have provided four years of data 
exclusivity and eight years of market exclusivity.  None of these 
bills, however, were passed in the 110th Congress.261 
 
 253 Id. 
 254 H.R. 1038, 110th Cong. (2007). 
 255 Id. § 3(k)(1)(C). 
 256 See Zuhn, supra note 251. 
 257 H.R. 1956, 110th Cong. § 2(k)(5)(B) (2007). 
 258 See Zuhn, supra note 251. 
 259 S. 1695, 110th Cong. § 2(k)(2)(A)(i) (2007). 
 260 Id.; see Zuhn, supra note 251. 
 261 See supra text accompanying note 252. 
GOLDBERG_NOTE_123009_FINAL (DO NOT DELETE) 12/30/2009  10:48:32 AM 
360 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. [Vol. 20:327 
A Teva-funded study262 suggested that an exclusivity period of 
seven years would be “sufficient for maintaining strong incentives 
to innovate while fostering a competitive marketplace.”263  Teva 
also questioned the need for exclusivity provisions that would add 
an additional seven to twelve years of protection.264  However, 
innovative companies have been supportive of bills that provide 
twelve to fourteen years of exclusivity.265  Thus, these studies 
illustrate the disconnect between innovative and generic companies 
regarding exclusivity periods. 
D. A Professor’s View 
Dr. Richard G. Frank, a leader in the field of health 
economics,266 has expressed that “the Hatch-Waxman framework 
is not sufficient to cover both relatively simple biopharmaceuticals 
and very large and complex molecules—a new regulatory 
framework is needed.”267  While he acknowledges that the loss of 
patent protection increases the urgency for regulatory policy 
promoting price competition and preserving the safety and efficacy 
standards,268 he states that the FDA should receive a “great deal of 
discretion” in making multifaceted, situation-specific judgments.269  
Thus, “the conflicting goals of bolstering price competition in 
biopharmaceutical markets and preserving for a nuanced policy 
that must be based on the best science and key features of the 
current economics of biopharmaceutical markets—not on the 
impassioned claims of the interested parties,”270 create a difficult 
set of parameters that requires situation-specific balancing. 
 
 262 Teva is a leading company that specializes in follow-on drugs. Posting of Elysa 
Brooke Goldberg, Ph.D. to IPLJ Law Blog, http://iplj.net/blog/archives/381 (Apr. 14, 
2009). 
 263 ALEX M. BRILL, PROPER DURATION OF DATA EXCLUSIVITY FOR GENERIC BIOLOGICS 3 
(2008), available at http://www.tevadc.com/Brill_Exclusivity_in_Biogenerics.pdf. 
 264 See generally id. 
 265 See id. at 6 (discussing Eshoo Bill). 
 266 Richard G. Frank, Ph.D., Regulation of Follow-On Biologics, 357 NEW ENG. J. MED. 
841, 843 (2007), available at http://content.nejm.org/cgi/content/short/357/9/841. 
 267 Id. 
 268 Id. 
 269 Id. 
 270 Id. 
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Dr. Frank interestingly advocates giving the FDA the 
discretion to permit generic biologics, instead of problematically 
simplifying the approval process via the Hatch-Waxman Act.271  
Dr. Frank hypothesizes that if the FDA were to require clinical 
studies of generic biologics, then the health of the community 
would be a top priority.272  In contrast, he believes that if the 
bioequivalence of the complex protein structures were the main 
deciding factor alone, the activity of the protein would not be 
considered.273  In this way, clinical trials would examine how 
effective the follow-on biologic is and be able to compare the 
biologic’s strength to the original brand-name biologic. 274 
E. Comparing a Patient’s and a Doctor’s View 
Thus far, the analysis of this paper addresses if the generics 
will be permitted to compete with brand-name pharmaceutical 
biologics using today’s legislation.  Another question to 
complicate the story is: will doctors prescribe the potential 
biosimilar in place of the innovative biologic?  Doctors who do not 
feel comfortable substituting the generic for the brand-name 
biologic could disarm the entrance of biosimilars into the 
market.275 
Data strongly suggests that both doctors and patients harbor 
brand loyalties.276  Many studies analyze patients’ choice to 
purchase brand-name pharmaceuticals instead of generic 
equivalents.277  One theory is that patients believe generic drugs, 
 
 271 Id. 
 272 Id. 
 273 See id. 
 274 Corbitt, supra note 7, at 388. 
 275 See GOV’T ACCOUNTABILITY OFFICE, PRESCRIPTION DRUGS: IMPROVEMENT NEEDED 
IN FDA’S OVERSIGHT OF DIRECT-TO-CONSUMER ADVERTISING 1–4 (2006), available at 
http://www.gao.gov/new.items/d0754.pdf (noting the increase in Direct-to-Consumer 
(“DTC”) advertising since 1997 and the implications of this trend for medical 
professionals).  
 276 William H. Shrank, Emily R. Cox, Michael A. Fischer, Jyotsna Mehta & Niteesh K. 
Chaudhry, Patients’ Perceptions of Generic Medications, 28 HEALTH AFFAIRS 546, 546 
(2009) (reporting results from a study sample regarding patients’ perceptions about 
generic drug substitutions). 
 277 Id. 
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priced lower than brand-name drugs, are of inferior quality.278  A 
telling study performed in 2000 found that “[t]he percentage of 
respondents who perceived that generic prescription drugs were 
riskier than brand name products varied from 14.2% to 53.8%, 
depending on the medical condition being treated.”279  In 2005, 
another study found that “37% of patients expressed general 
skepticism towards generic drugs because of their lower price.”280  
Therefore, many patients ultimately decide against the benefit of 
savings offered by generic drugs and instead pay higher prices for 
brand-name drugs.281 
When faced with the decision to prescribe generics over name-
brand pharmaceuticals, physicians conduct themselves similarly to 
patients.282  One theory is that physicians tend to be risk-averse and 
would prefer not creating variability in patient treatment.283  
Physicians have long been criticized as being “creatures of 
habit.”284  Such character traits make it difficult to prescribe 
generic drugs.  However, such caution is well founded.  Organic 
chemistry has shown that “polymorphism” frequently occurs when 
generating drugs.285  Polymorphism is the ability of drugs to exist 
in many different types of crystalline phases, all having different 
reactivity.286  FDA scientists know that such a cocktail of different 
crystalline phases can affect drug stability and drug activity.287  
 
 278 Rebecca Ruiz, What You Should Know About Generic Drugs, FORBES, July 27, 
2009, http://www.forbes.com/2009/07/27/generic-drugs-prescriptions-lifestyle-health-
drugs.html. 
 279 Julie M. Ganther & David H. Kreling, Consumer Perceptions of Risk and Required 
Cost Savings for Generic Prescription Drugs, 40 J. AM. PHARM. ASS’N 378, 378 (2000). 
 280 W. Himmel et al., What Do Primary Care Patients Think About Generic Drugs?, 43 
INT’L J. CLINICAL PHARMACOLOGY & THERAPEUTICS 472, 472 (2005). 
 281 Id. 
 282 See id. at 477 (“[P]atients as well as physicians do not have the incentive to invest in 
low-cost treatment as long as insurance companies pay the costs of prescription, 
regardless of their generic or brand-name status.”). 
 283 F.M. Scherer, Pricing, Profits, and Technological Progress in the Pharmaceutical 
Industry, 7 J. ECON. PERSP. 97, 101 (1993). 
 284 Id. 
 285 Scientific Considerations of Polymorphism in Pharmaceutical Solids: Abbreviated 
New Drug Applications, http://www.fda.gov/ohrms/dockets/ac/02/briefing/3900B1_04_ 
Polymorphism.htm (last visited Aug. 30, 2009). 
 286 Id. 
 287 Id. 
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Thus, physicians have good reason to question the ability of 
generic drugs to perform comparably to brand-name 
pharmaceuticals. 
While in theory an active ingredient has the same function and 
potency regardless of being brand-name or generic, it is ultimately 
the patient that needs to determine if the small molecule is acting 
identically.  Many patients have noted that they can identify 
differences in the potency of brand-name versus generic drugs.288 
Because patients question the quality of generic drugs and 
physicians err on the side of caution, more brand-name drugs are 
routinely prescribed instead of an identical authorized generic to 
avoid potential tort liability.289  The fact that generics are poorly 
regarded in a percentage of the medical field and in society raises 
the question of whether doctors would substitute for and patients 
would request follow-on biologics for brand-name biologics.290 
On behalf of the innovative brand-name pharmaceutical 
companies, the Biotechnology Industry Organization (BIO) is 
concerned about doctors being stripped of choice.291  The Waxman 
Bill will permit biosimilars to be substituted for the innovative 
biologic without the intervention of the prescribing doctor.292  The 
generic biologic may be permitted as a substitute without the 
doctor’s approval, which could ultimately limit the doctor’s control 
and treatment of the patient. 
 
 288 See Road Back Foundation, Are Generic Drugs as Effective as Brand Name?—Not 
Always!, http://www.roadback.org/index.cfm/fuseaction/education.display/display_id/ 
120.html (last visited Aug. 30, 2009). 
 289 Thomas Chen, Authorized Generics: A Prescription for Hatch-Waxman Reform, 93 
VA. L. REV. 459, 477 (2007). 
 290 Id. 
 291 See BIO, supra note 24. 
 292 Jonathan Sheffi, What Are Follow-On Biologics? Will They Really Save Us Billions 
of Dollars?, The Soul of Biotech (June 29, 2009), http://www.thesoulofbiotech 
.com/2009/06/29/what-are-follow-on-biologics-will-they-really-save-us-billions-of-
dollars/. 
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F. Brand-Name Perspective: Impossibility of Duplication and the 
Question of Patentability 
Although patent protection is available for biologics in many 
circumstances, there may be a limited scope of protection.293  The 
patent system further regulates competition in the biologics 
market, as there may be restrictions on the availability of 
proprietary rights in biological substances.294  The 110th Congress 
reviewed legislation295 that would permit an expedited marketing 
approval pathway.296  The Access to Life-Saving Medicine Act, 
House Bill 1038 and Senate Bill 623, would have permitted the 
Secretary of Health and Human Services to monitor what studies 
were necessary to establish comparability.297  Comparable 
biologics would be necessary to maintain the same chemical 
reaction, the same mechanism of performing this reaction, as well 
as the same dosage form, strength, etc.298  While the identical 
chemical reaction and mechanism for reaction would be relatively 
easy to prove, the same dosage form and strength could be very 
tricky to establish.299  If all of these parameters were to be met, 
then the generic form of the brand-name biologic would be deemed 
“interchangeable.”300  An interchangeable product would be 
required to produce the same clinical results as the brand-name 
innovative drug.301 
There is a formidable lobby, lead by the Intellectual Property 
Owners Association, against approval of follow-on biologics, 
which strongly asserts that it is impossible to replicate a brand-
name pharmaceutical’s biological innovations exactly, due to 
 
 293 WENDY H. SCHACHT & JOHN R. THOMAS, FOLLOW-ON BIOLOGICS: INTELLECTUAL 
PROPERTY AND INNOVATION ISSUES 2 (2008), available at https://www.policyarchive.org/ 
bitstream/handle/10207/3161/RL33901_20070305.pdf. 
 294 Id. 
 295 See supra notes 252–61 and accompanying text. 
 296 See supra Part III.C. 
 297 S. 623, 110th Cong. (2007); H.R. 1038, 110th Cong. (2007). 
 298 S. 623, 110th Cong. (2007); H.R. 1038, 110th Cong. (2007). 
 299 See supra note 93.   
 300 See supra note 93. 
 301 See supra note 93. 
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technological limitations.302  The crux of this argument lies in 
health and safety concerns, and proponents of this view advocate 
against an accelerated approval process for follow-on biologics.303  
These pharmaceutical companies assert that an end product is 
unpredictable, even with guidance through patent disclosures, 
including deposited biological samples.304  This argument 
stipulates that since it is impossible to recreate the innovative 
biologic perfectly, patent protection should not apply.305 
While the safety and health of patients is a strong aspect of this 
argument, considering only safety and health undercuts the 
patentability of the biologic.  Enablement is a fundamental step in 
securing patentability.306  If it is impossible to replicate the 
patented invention, then there is a prima facie case against 
patenting the invention due to non-enablement.307  Using the 
inability to fulfill the enablement requirement as an argument 
weakens incentives to patent inventions and is unfair.  If brand-
name pharmaceuticals were unable to be patented, companies 
would instead use the power of trade secrets to insulate them from 
competition.308  Protecting brand-name pharmaceuticals through 
trade secrets would drive down the amount of information 
available to any pharmaceutical company regarding any type of 
technique.309  Consequently, it would be more unlikely that 
 
 302 Letter from Herbert C. Wamsley, Executive Director, Intellectual Property Owners 
Association, to Anna Eshoo, U.S. H. Rep. (July 17, 2009), available at 
http://www.ipo.org/AM/Template.cfm?Section=Board_Resolutions_and_Position_State
ments&TEMPLATE=/CM/ContentDisplay.cfm&CONTENTID=23296 (memorializing 
the IPO’s support for House Bill 1548). 
 303 Donald Zuhn, IPO Passes Resolution on Biosimilars, PATENT DOCS, Sept. 23, 2008 
http://www.patentdocs.org/2008/09/follow-on-biolo.html. 
 304 Corbitt, supra note 7, at 397. 
 305 See Stephen B. Judlowe & Brian P. Murphy, IP VALUE 2005, Proposed Legislation 
for Follow-On Biologic Pharmaceuticals in the US, http://www.buildingipvalue.com/ 
05_NA/135_138.htm. 
 306 35 U.S.C. § 112 (2006).  For a description of the enablement requirement, see 
United States Patent and Trademark Office, The Enablement Requirement, 
http://www.uspto.gov/web/offices/pac/mpep/documents/2100_2164.htm (last visited on 
Oct. 14, 2009) [hereinafter The Enablement Requirement]. 
 307 See The Enablement Requirement, supra note 306. 
 308 Corbitt, supra note 7, at 398. 
 309 See id. 
GOLDBERG_NOTE_123009_FINAL (DO NOT DELETE) 12/30/2009  10:48:32 AM 
366 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. [Vol. 20:327 
competitors would be able to manufacture follow-on biologics.310  
Additionally, reverse-engineering would be nearly impossible, so 
trade secrets would be a workable way to protect such intellectual 
property.  If inventions and innovations were protected by trade 
secret and not patent law, generic equivalents would be impossible 
to generate unless the secrets, for example, were sold. 
A major flaw with not extending patentability to innovations 
that are very difficult to reproduce is that the innovators no longer 
have the protection of a patent.  Losing the availability of patent 
rights could very likely be a large disincentive to continue funding 
pharmaceutical companies and their research and development 
efforts.  The rights of patents extend from literal infringement 
through the doctrine of equivalence (“DOE”).311  The DOE is only 
available to patented products, not to those covered via trade secret 
because patented innovations are extended protections that trade 
secrets are not.312  The DOE allows a court to hold a party liable 
for patent infringement for an equivalent to the claimed 
invention.313  Courts may use the DOE to stop companies from 
avoiding infringing patents by making insubstantial changes to the 
innovation.314  Without the DOE, the value of patents “would be 
greatly diminished.”315 
 
 310 Id. (“If enablement is itself impossible, then trade secret protection might be more 
advisable than patent protection, as reverse engineering such a complicated process is 
highly improbable.”). 
 311 See ROBERT P. MERGES, PETER S. MENELL & MARK A. LEMLEY, INTELLECTUAL 
PROPERTY IN THE NEW TECHNOLOGICAL AGE 263–64 (4th ed. 2006) (describing how the 
doctrine of equivalents expands on patent protection against literal infringement). 
 312 United States Patent and Trademark Office, General Information Concerning 
Patents, http://www.uspto.gov/go/pac/doc/general/#nature (last visited Sept. 27, 2009) 
(stating that patent protection refers to the right to exclude others from making, using, 
offering for sale or selling or importing the invention). 
 313 Royal Typewriter Co. v. Remington Rand, Inc., 168 F.2d 691, 692 (2d Cir. 1948). 
 314 Id. 
 315 Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722, 731 (2002). 
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III. COME TOGETHER: THE UNITED STATES SHOULD MAINTAIN THE 
CURRENT BALANCE INHERENT IN PATENT LAW AND NOT SACRIFICE 
HEALTH FOR SPEEDY PRICE COMPETITION 
Congress should implement key changes to the Hatch-Waxman 
Act to monitor and address the primary concern of health.  While 
Congress has written and evaluated many bills, it has not found a 
solution that opposing sides can agree upon.  It is imperative that 
the urgency of supplying cheaper biologics does not supersede the 
requirement for safe and effective medication.  The long-term goal 
is for innovative research to maintain incentives to bring life-
saving biologics to Americans; without this incentive, Americans 
will ultimately be the losers. 
A. The Lines of Communication Are Open 
A passable bill “should adequately compensate generic 
manufacturers by providing at least some exclusivity for biologic 
products.”316  All of the proposed Congressional bills had 
drawbacks, either because they had too much exclusivity (House 
Bill 1038 and Senate Bill 1695) or did not have any (House Bill 
1956),317 and consequently, these bills were not passed.318  Until 
there is a thoughtful conversation between both of these 
approaches, the innovative pharmaceutical companies will enjoy a 
market without competition from follow-on biologics.319  
Considering that both innovative and generic pharmaceutical 
companies have an interest in maximizing gross revenue, it is 
encouraging that a thoughtful bipartisan discussion has already 
ensued via the 110th Congress.320 
The writers of the Eshoo Bill have considered many points of 
contention from the previous 110th Congress and have softened 
 
 316 Kelleher, supra note 43, at 262. 
 317 See supra text accompanying notes 252–61. 
 318 See supra text accompanying note 262. 
 319 See Waxman, supra note 137. 
 320 Orrin G. Hatch, U.S. Sen., Now is the Time to Act: The Urgent Need to Pass S. 
1695 in the 110th Congress (Sept. 22, 2008), http://www.biosimilarstoday.com/ 
2008/Hatch.pdf. 
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the bill’s stance accordingly.321  An interesting twist in the Eshoo 
Bill is that experimentation is not required, as this bill states that it 
could be waived.322  It seems as though the 110th Congress’s 
struggle with this issue can be shelved because of this concession.  
The most hotly contested issue of the upcoming 111th Congress 
will be the exclusivity provision.323  There is a large discrepancy 
between five or twelve years of exclusivity, and negotiation to 
reach a term will not be easy.  The longer term of exclusivity 
provides the ability for follow-on biologic companies to follow 
through with additional experimentation,324 a possibility that would 
not exist if the five-year exclusivity term were adopted.  Thus, the 
writers of the Eshoo Bill have already taken into consideration the 
lessons of the 110th Congress and have made the concession of 
mandatory experimentation.  Any additional concession of the 
Eshoo Bill, specifically the exclusivity of innovative biologics, 
would drastically undermine consumer safety. 
B. Consumer Safety 
Generic pharmaceutical companies’ strong interest in creating 
affordable biologics can be one-sided, in both the short and long-
term.  By not being subject to the standard testing procedures, the 
follow-on biologic could adversely affect patients.325  Thus, by not 
requiring additional experimentation, we are undermining the 
public’s need for safe medicine.  Additionally, innovative 
companies producing these pioneer biologics would not profit 
 
 321 Kurt R. Karst, FDA Law Blog, Rep Eshoo Proposes Draft Biogenerics Bill (Feb. 18, 
2000), http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2009/03/rep-eshoo-
introduces-followon-biologics-bill-proposed-pathway-for-biosimilars-act-is-reportedly-
simi.html.  Rep. Anna Eshoo (D-CA), Rep. Jay Inslee (D-WA) and Rep. Joe Barton (R-
TX) are the authors of the Eshoo Bill. 
 322 Karst, supra note 321. 
 323 See supra note 251 and accompanying text. 
 324 See supra text accompanying notes 209–14. 
 325 See Corbitt, supra note 7, at 397–98 (“Executives from large pharmaceutical 
corporations . . . have testified before congressional committees and cited public health 
and safety as a reason to halt the approval of an expedited approval process for 
biosimilars.  They claim that there is no possible way to exactly and safely copy their 
results.”). 
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nearly as much as they would have in the past.326  As a result, those 
companies will have less incentive to invest in cutting-edge 
research to develop new, potentially life-saving medicines.327  If 
Congress does not strike a balance between innovative and follow-
on biologics, then the public is at risk to receive dangerous follow- 
on biologics, and innovative pharmaceutical companies will not 
have the resources to invest into research and development. 
Considering that both the Waxman Bill and Eshoo Bill have 
compromised on the requirement of additional experimentation for 
follow-on biologics, exclusivity is the next obvious issue of 
contention.  Since companies generating follow-on biologics 
would be able to cut years off of the process of getting biologic 
products to store shelves,328 these companies would surely want 
shorter periods of innovative drug exclusivity.  A short five-year 
period of exclusivity is not desirable because it would undermine 
the possibility of additional experimentation that the Eshoo Bill 
provides.329  A longer period of exclusivity is crucial, as the Eshoo 
Bill suggests, because this Bill innately provides additional time 
for the follow-on manufacturer to test its biological product.  In 
this way, Congress can better achieve consumer health and safety 
in both the short and long-term. 
C. Preservation of Incentives for Innovative Drug Companies 
An underlying priority must be to promote continued research 
and development in the fields of biotechnology.  Thus, American 
patents must be strong and reliable, protecting the intellectual 
property that they breed.  If American patents are not as strong as 
foreign patents or if there is significant uncertainty as to how 
 
 326 See id. at 390–91 (proposing that production of biosimilars may not be economically 
efficient because its development costs are much higher than the development costs of a 
small-molecule generic); see also Scherer, supra note 283, at 103–06 (“[M]ost [new 
products] achieve much lower sales. . . .  [N]ew drug development resembles a risky 
lottery that throws out rich rewards to a few big winners while the majority of entries lose 
money.”). 
 327 Corbitt, supra note 7, at 390–91. 
 328 Press Release, Federal Trade Commission, FTC Releases Report on “Follow-on 
Biologic Drug Competition” (June 10, 2009), http://www.ftc.gov/opa/2009/06/biologics. 
shtm. 
 329 H.R. 1427, 111th Cong. (2009). 
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inventors will interpret American patents, inventors will quickly 
lose incentive to continue filing in the United States.  Thus, 
protecting innovation by approving patents for biologics is 
mandatory for continued industry and research growth.330 
The example of insulin331 highlights why patent protection is 
so important for biological research, as it took almost twenty years 
for Eli Lilly to purify insulin and successfully obtain approval to 
market this therapy.332  If the leaders within Eli Lilly knew that 
their purified insulin would ultimately never receive patent 
protection, they may not have invested almost two decades of 
research in this field.  Additionally, Eli Lilly may not have pursued 
purification of naturally occurring biological proteins if their patent 
rights were abbreviated and if they knew that generics would 
immediately compete with their twenty years of hard work and 
investment. 
A final issue that needs to be addressed is whether abbreviating 
the period of patent protection is an unconstitutional taking without 
just compensation.333  Permitting pharmaceutical companies 
manufacturing generics to take and use the discoveries of 
innovative pharmaceuticals presents a strong argument for an 
unconstitutional taking.334  Considering that huge amounts of 
money are invested by brand-name pharmaceuticals for research 
and development, there needs to be some reasonable compensation 
for the discoveries. 
CONCLUSION 
The Biologics Act of 2007 first attempted to mold the Hatch-
Waxman Act into a vehicle previously encompassing tiny, simple 
drugs into an extension for large, complex biological molecules.335  
 
 330 Corbitt, supra note 7, at 400. 
 331 “Deducing the steps required to purify and produce insulin, for example, took 
considerable work by some of the top scientists in the field.” Id. at 402. 
 332 Id. 
 333 Id. 
 334 See Monsanto Co. v. Acting Admin. U.S. EPA, 564 F. Supp. 552, 566–67 (E.D. Mo. 
1983) (holding that the government attempted an unconstitutional taking of an innovator 
manufacturer’s property right when requiring information held in trade secret). 
 335 See supra text accompanying notes 137–44. 
GOLDBERG_NOTE_123009_FINAL (DO NOT DELETE) 12/30/2009  10:48:32 AM 
2009] FIXING A HOLE 371 
However, the question remains whether applying the Biosimilars 
Act to the established Hatch-Waxman process of approval and 
generic manufacture would be beneficial.  The past and current 
bills seek that generic biologics manufacturers satisfy further 
requirements, such as conducting extensive clinical studies, which 
will increase the biosimilar’s costs and decrease the margin 
between the price of the innovative biologic and the follow-on 
generic.336  Both bills have been referred to the House Energy and 
Commerce Committee and the House Judiciary Committee.337 
An additional concern, besides higher manufacturing costs and 
decreased profits, is the actual market for follow-on biologics.  
Doctors and patients alike have reservations about using generic 
drugs in place of brand-name drugs.  There is no way to predict 
how follow-on biologics will be accepted by the general public; 
will follow-on biologics be embraced as cheaper alternatives, or 
will they be rejected because of potential health concerns?  Passing 
the Eshoo Bill or the Waxman Bill will answer this lingering 
question.  Because of these concerns, it is unclear whether the 
follow-on biologic market will be as robust a competitor as the 
generic small-molecule market.  Clearly, if a follow-on biologic 
market broadens due to the passing of the Biologics Act, it is of the 
utmost importance that these generic biological medicines are safe 
for consumer use.  Therefore, it is in the best interest of consumers 
to demand experimentation.  Experimentation requires time, and 
the Eshoo Bill provides this needed time.  The Eshoo Bill carefully 
and clearly lays out the regulation of biosimilars, additionally 
leaving room for variation in experimentation requirements.  The 
Eshoo Bill best anticipates the needs of the American people and 
must be voted for in the upcoming 111th Congress. 
 
 
 336 See supra notes 195–216 and accompanying text; see also H.R. 1427, 111th Cong. 
(2009). 
 337 H.R. 1548, 111th Cong. (2009). 
